Evidence map›Paper›PMID 35457168›Full record

ReviewInternational journal of molecular sciences2022

Glucose Metabolism, Neural Cell Senescence and Alzheimer's Disease.

Qianqian Wang, Linyan Duan, Xingfan Li, Yifu Wang, Wenna Guo, Fangxia Guan, Shanshan Ma

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 79 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Restoring glucose metabolism in Alzheimer's disease by targeting integrated stress response.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Qianqian WangSchool of Life Sciences, Zhengzhou University, Zhengzhou 450001, China.
Linyan DuanSchool of Life Sciences, Zhengzhou University, Zhengzhou 450001, China.
Xingfan LiSchool of Life Sciences, Zhengzhou University, Zhengzhou 450001, China.
Yifu WangSchool of Life Sciences, Zhengzhou University, Zhengzhou 450001, China.
Wenna GuoSchool of Life Sciences, Zhengzhou University, Zhengzhou 450001, China.
Fangxia GuanSchool of Life Sciences, Zhengzhou University, Zhengzhou 450001, China.
Shanshan MaSchool of Life Sciences, Zhengzhou University, Zhengzhou 450001, China.ORCID 0000-0002-0780-4568
Zhengzhou University · CN

Funding

Central Plains Thousand People Plan of Henan Province 204200510013Henan Overseas Expertise Introduction Center for Discipline Innovation CXJD2021002National Natural Science Foundation of China U2004201The Key Science and Technology Research Project of Henan Province of China 212102310175
6 · The paper itself

Abstract

Alzheimer's disease (AD), an elderly neurodegenerative disorder with a high incidence and progressive memory decline, is one of the most expensive, lethal, and burdening diseases. To date, the pathogenesis of AD has not been fully illustrated. Emerging studies have revealed that cellular senescence and abnormal glucose metabolism in the brain are the early hallmarks of AD. Moreover, cellular senescence and glucose metabolism disturbance in the brain of AD patients may precede amyloid-β deposition or Tau protein phosphorylation. Thus, metabolic reprogramming targeting senescent microglia and astrocytes may be a novel strategy for AD intervention and treatment. Here, we recapitulate the relationships between neural cell senescence and abnormal glucose metabolism (e.g., insulin signaling, glucose and lactate metabolism) in AD. We then discuss the potential perspective of metabolic reprogramming towards an AD intervention, providing a theoretical basis for the further exploration of the pathogenesis of and therapeutic approach toward AD.

Indexed as

Alzheimer DiseaseAgedAmyloid beta-PeptidesBrainCellular SenescenceGlucoseHumansNeuronsAmyloid beta-PeptidesGlucoseAlzheimer’s diseaseglucose metabolismmetabolic reprogrammingneural cell senescencetherapeutics

Identifiers

PMID35457168
PMCPMC9030802
OpenAlexW4224072296

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.